Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Souery

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Current Medicinal Chemistry|January 5, 2021
Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in DepressionMarco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 2, 2020
Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic studyChiara Fabbri, Siegfried Kasper, Joseph Zohar, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|December 24, 2014
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopramDaniel Souery, Raffaella Calati, Konstantinos Papageorgiou, et al.
Journal of Affective Disorders|March 23, 2023
Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorderLucie Bartova, Gernot Fugger, Markus Dold, et al.
Brain, Behavior, and Immunity|March 5, 2017
Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depressionOle Köhler-Forsberg, Henriette N Buttenschøn, Katherine E Tansey, et al.
Journal of Affective Disorders|March 18, 2011
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptylineRudolf Uher, Mojca Zvezdana Dernovsek, Ole Mors, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 6, 2003
Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European studyPierre Oswald, Daniel Souery, Isabelle Massat, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 24, 2018
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samplesChiara Fabbri, Siegfried Kasper, Alexander Kautzky, et al.
Psychiatric Genetics|February 26, 2025
A machine learning approach to predict treatment efficacy and adverse effects in major depression using CYP2C19 and clinical-environmental predictorsMarco Calabrò, Chiara Fabbri, Alessandro Serretti, et al.
Psychiatry Research|December 21, 2010
No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depressionAlessandro Serretti, Alberto Chiesa, Raffaella Calati, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Current Medicinal Chemistry|January 5, 2021
Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in DepressionMarco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 2, 2020
Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic studyChiara Fabbri, Siegfried Kasper, Joseph Zohar, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|December 24, 2014
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopramDaniel Souery, Raffaella Calati, Konstantinos Papageorgiou, et al.
Journal of Affective Disorders|March 23, 2023
Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorderLucie Bartova, Gernot Fugger, Markus Dold, et al.
Brain, Behavior, and Immunity|March 5, 2017
Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depressionOle Köhler-Forsberg, Henriette N Buttenschøn, Katherine E Tansey, et al.
Journal of Affective Disorders|March 18, 2011
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptylineRudolf Uher, Mojca Zvezdana Dernovsek, Ole Mors, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 6, 2003
Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European studyPierre Oswald, Daniel Souery, Isabelle Massat, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 24, 2018
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samplesChiara Fabbri, Siegfried Kasper, Alexander Kautzky, et al.
Psychiatric Genetics|February 26, 2025
A machine learning approach to predict treatment efficacy and adverse effects in major depression using CYP2C19 and clinical-environmental predictorsMarco Calabrò, Chiara Fabbri, Alessandro Serretti, et al.
Psychiatry Research|December 21, 2010
No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depressionAlessandro Serretti, Alberto Chiesa, Raffaella Calati, et al.
Pageof 17